These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32627129)

  • 1. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience.
    Cacciotti C; Choi J; Alexandrescu S; Zimmerman MA; Cooney TM; Chordas C; Clymer J; Chi S; Yeo KK
    J Neurooncol; 2020 Aug; 149(1):113-122. PubMed ID: 32627129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab in the Treatment of Recurrent or Refractory Pediatric Brain Tumors: A Single Institutional Experience.
    Gorsi HS; Malicki DM; Barsan V; Tumblin M; Yeh-Nayre L; Milburn M; Elster JD; Crawford JR
    J Pediatr Hematol Oncol; 2019 May; 41(4):e235-e241. PubMed ID: 30681550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.
    Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK
    J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
    Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.
    Becher OJ; Millard NE; Modak S; Kushner BH; Haque S; Spasojevic I; Trippett TM; Gilheeney SW; Khakoo Y; Lyden DC; De Braganca KC; Kolesar JM; Huse JT; Kramer K; Cheung NV; Dunkel IJ
    PLoS One; 2017; 12(6):e0178593. PubMed ID: 28582410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
    Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
    Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reirradiation for Recurrent Pediatric Central Nervous System Malignancies: A Multi-institutional Review.
    Rao AD; Rashid AS; Chen Q; Villar RC; Kobyzeva D; Nilsson K; Dieckmann K; Nechesnyuk A; Ermoian R; Alcorn S; MacDonald SM; Ladra MM; Ford EC; Winey BA; Figueiredo MLS; Chen MJ; Terezakis SA
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):634-641. PubMed ID: 29280457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience.
    Kline C; Liu SJ; Duriseti S; Banerjee A; Nicolaides T; Raber S; Gupta N; Haas-Kogan D; Braunstein S; Mueller S
    J Neurooncol; 2018 Dec; 140(3):629-638. PubMed ID: 30206764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
    Gorsi HS; Khanna PC; Tumblin M; Yeh-Nayre L; Milburn M; Elster JD; Crawford JR
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.
    Salloum R; Hummel TR; Kumar SS; Dorris K; Li S; Lin T; Daryani VM; Stewart CF; Miles L; Poussaint TY; Stevenson C; Goldman S; Dhall G; Packer R; Fisher P; Pollack IF; Fouladi M; Boyett J; Drissi R
    J Neurooncol; 2016 Sep; 129(3):443-451. PubMed ID: 27350411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
    Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
    Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
    Lin FY; Stuckert A; Tat C; White M; Ruggieri L; Zhang H; Mehta B; Lapteva N; Mei Z; Major A; Thakkar S; Shum T; Parikh K; Wu MF; Lindsay HB; Scherer L; Shekar M; Baxter P; Wang T; Grilley B; Moeller K; Hicks J; Roy A; Anastas J; Malbari F; Aldave G; Chintagumpala M; Blaney S; Parsons DW; Brenner MK; Heslop HE; Rooney CM; Omer B
    J Clin Oncol; 2024 Aug; 42(23):2769-2779. PubMed ID: 38771986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective study of nivolumab for patients with recurrent high grade gliomas.
    Mantica M; Pritchard A; Lieberman F; Drappatz J
    J Neurooncol; 2018 Sep; 139(3):625-631. PubMed ID: 29779086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.
    Manley PE; Trippett T; Smith AA; Macy ME; Leary SES; Boklan J; Cohen KJ; Goldman S; Kilburn LB; Dhall G; Devin J; Herzog CE; Partap S; Fauchet F; Badreddine E; Bernard JP; Chi SN
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27217. PubMed ID: 29750396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group.
    MacDonald TJ; Vezina G; Stewart CF; Turner D; Pierson CR; Chen L; Pollack IF; Gajjar A; Kieran MW
    Neuro Oncol; 2013 Oct; 15(10):1438-44. PubMed ID: 24014381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
    Lulla RR; Goldman S; Yamada T; Beattie CW; Bressler L; Pacini M; Pollack IF; Fisher PG; Packer RJ; Dunkel IJ; Dhall G; Wu S; Onar A; Boyett JM; Fouladi M
    Neuro Oncol; 2016 Sep; 18(9):1319-25. PubMed ID: 27022131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nimotuzumab therapy in the treatment of pediatric central nervous system tumors: single-center experience.
    Susam-Sen H; Varan A; Bajin İ; Göçmen R; Aydın B; Yalcin B; Kurucu N; Kutluk T; Bayhan T; Akyuz C
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Aug; 394(8):1769-1777. PubMed ID: 34151393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma.
    Ehlert K; Hansjuergens I; Zinke A; Otto S; Siebert N; Henze G; Lode H
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single-center experience.
    Wei D; Zhou DJ; Datta P; Taraschenko O
    Cancer Med; 2021 May; 10(9):2978-2986. PubMed ID: 33660430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.